{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:08Z","timestamp":1792788068670,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TKI Life Sciences & Health"},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["09150161910230"],"award-info":[{"award-number":["09150161910230"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pompe disease is a lysosomal storage disease treated with life-long enzyme replacement therapy (ERT). Home-based ERT has been provided in the Netherlands since 2008 because it diminishes the burden of treatment, increases patient flexibility and autonomy, and is thus a more patient-centred approach to ERT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All Dutch Pompe patients receiving alglucosidase alfa infusions at home were approached to participate in a questionnaire to validate the safety of home-based ERT. Prospective data on symptoms occurring during or within 48\u00a0h after infusion and retrospective data on infusion associated reactions (IARs) in the last three months were collected four times during one year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 116 out of 120 eligible patients (17 classic infantile, 2 atypical infantile, 15 childhood onset and 82 adult) filled out 423 questionnaires (response rate: 88.1%). Symptoms during or after infusion were reported 27 times in 17 patients. Fatigue was the most commonly reported health complaint (in 9.5% of patients). Four health complaints were judged to be IARs and reported to the Erasmus MC University Medical Center. None of the IARs reported in this study warranted emergency clinical care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data demonstrate that home-based ERT in Pompe disease can be safely implemented as few, mostly mild, symptoms were reported during or after infusion. Insights from this study can be used as a base for implementing home-based ERT in other countries and to further optimize patient care, as unreported mild symptoms do not pose a health risk but may still be relevant to the patient.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02715-4","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T12:03:35Z","timestamp":1683547415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study"],"prefix":"10.1186","volume":"18","author":[{"given":"Imke A. M.","family":"Ditters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine A. M. E.","family":"van der Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Brusse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M. P.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1276-0931","authenticated-orcid":false,"given":"Hidde H.","family":"Huidekoper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"issue":"9646","key":"2715_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ. Pompe\u2019s disease. Lancet. 2008;372(9646):1342\u201353.","journal-title":"Lancet"},{"issue":"2","key":"2715_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ajmg.a.35662","volume":"161A","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, Reuser AJ. How to describe the clinical spectrum in Pompe disease? Am J Med Genet A. 2013;161A(2):399\u2013400.","journal-title":"Am J Med Genet A"},{"issue":"2","key":"2715_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1067\/mpd.2000.107112","volume":"137","author":"AE Slonim","year":"2000","unstructured":"Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr. 2000;137(2):283\u20135.","journal-title":"J Pediatr"},{"issue":"8","key":"2715_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","volume":"252","author":"LP Winkel","year":"2005","unstructured":"Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, et al. The natural course of non-classic Pompe\u2019s disease; a review of 225 published cases. J Neurol. 2005;252(8):875\u201384.","journal-title":"J Neurol"},{"key":"2715_CR5","doi-asserted-by":"crossref","unstructured":"In 't Groen SLM, de Faria DOS, Iuliano A, van den Hout JMP, Douben H, Dijkhuizen T, et al. Novel GAA Variants and Mosaicism in Pompe Disease Identified by Extended Analyses of Patients with an Incomplete DNA Diagnosis. Mol Ther Methods Clin Dev. 2020;17:337\u201348.","DOI":"10.1016\/j.omtm.2019.12.016"},{"issue":"9227","key":"2715_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","volume":"356","author":"H Van den Hout","year":"2000","unstructured":"Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356(9227):397\u20138.","journal-title":"Lancet"},{"issue":"2","key":"2715_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99\u2013109.","journal-title":"Neurology"},{"issue":"3","key":"2715_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","volume":"66","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66(3):329\u201335.","journal-title":"Pediatr Res"},{"key":"2715_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijcard.2018.07.091","volume":"269","author":"CI van Capelle","year":"2018","unstructured":"van Capelle CI, Poelman E, Frohn-Mulder IM, Koopman LP, van den Hout JMP, Regal L, et al. Cardiac outcome in classic infantile Pompe disease after 13years of treatment with recombinant human acid alpha-glucosidase. Int J Cardiol. 2018;269:104\u201310.","journal-title":"Int J Cardiol"},{"issue":"1","key":"2715_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S2352-4642(21)00308-4","volume":"6","author":"IAM Ditters","year":"2022","unstructured":"Ditters IAM, Huidekoper HH, Kruijshaar ME, Rizopoulos D, Hahn A, Mongini TE, et al. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium. Lancet Child Adolesc Health. 2022;6(1):28\u201337.","journal-title":"Lancet Child Adolesc Health"},{"issue":"15","key":"2715_CR11","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med. 2010;362(15):1396\u2013406.","journal-title":"N Engl J Med"},{"issue":"1","key":"2715_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","volume":"257","author":"S Strothotte","year":"2010","unstructured":"Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol. 2010;257(1):91\u20137.","journal-title":"J Neurol"},{"issue":"5","key":"2715_CR13","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","volume":"259","author":"C Angelini","year":"2012","unstructured":"Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol. 2012;259(5):952\u20138.","journal-title":"J Neurol"},{"issue":"3","key":"2715_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT van der Ploeg","year":"2012","unstructured":"van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ, et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab. 2012;107(3):456\u201361.","journal-title":"Mol Genet Metab"},{"key":"2715_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1750-1172-8-49","volume":"8","author":"D Gungor","year":"2013","unstructured":"Gungor D, Kruijshaar ME, Plug I, D\u2019Agostino RB, Hagemans ML, van Doorn PA, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis. 2013;8:49.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2715_CR16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","volume":"37","author":"LJ Anderson","year":"2014","unstructured":"Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek S, Hughes DA, et al. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. 2014;37(6):945\u201352.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"2715_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264(4):621\u201330.","journal-title":"J Neurol"},{"key":"2715_CR18","doi-asserted-by":"crossref","unstructured":"van der Meijden JC, Kruijshaar ME, Harlaar L, Rizopoulos D, van der Beek N, van der Ploeg AT. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. J Inherit Metab Dis. 2018.","DOI":"10.1007\/s10545-018-0166-3"},{"issue":"19","key":"2715_CR19","doi-asserted-by":"publisher","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","volume":"93","author":"L Harlaar","year":"2019","unstructured":"Harlaar L, Hogrel J-Y, Perniconi B, Kruijshaar ME, Rizopoulos D, Taouagh N, et al. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology. 2019;93(19):e1756\u201367.","journal-title":"Neurology"},{"issue":"11","key":"2715_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242630","volume":"15","author":"C Perraudin","year":"2020","unstructured":"Perraudin C, Bourdin A, Vicino A, Kuntzer T, Bugnon O, Berger J. Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: a Swiss cost-minimization analysis. PLoS ONE. 2020;15(11): e0242630.","journal-title":"PLoS ONE"},{"key":"2715_CR21","unstructured":"FDA. Highlights of prescribing information MYOZYME\u00ae (alglucosidase alfa) injectable for intravenous infusion: FDA [updated 05\u20132019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125141s219lbl.pdf."},{"key":"2715_CR22","unstructured":"Myozyme: EPAR - Product information: European Medicines Agency; 2022 [updated 25\u201308\u20132022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/myozyme-epar-product-information_en.pdf."},{"issue":"1s","key":"2715_CR23","first-page":"S250","volume":"9","author":"I Ditters","year":"2022","unstructured":"Ditters I, van Kooten H, van der Beek N, van der Ploeg A, van den Hout H, Huidekoper H. eP030502 Safety of home-based infusion of alglucosidase alfa in adults with late-onset Pompe disease. J Neuromuscul Dis. 2022;9(1s):S250-251.","journal-title":"J Neuromuscul Dis."},{"key":"2715_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/gim.2016.70","volume":"19","author":"JM de Vries","year":"2017","unstructured":"de Vries JM, Kuperus E, Hoogeveen-Westerveld M, Kroos MA, Wens SCA, Stok M, et al. Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy. Genet Med. 2017;19:90.","journal-title":"Genet Med"},{"issue":"6","key":"2715_CR25","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg AT, Kruijshaar ME, Toscano A, Laforet P, Angelini C, Lachmann RH, et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017;24(6):768-e31.","journal-title":"Eur J Neurol"},{"key":"2715_CR26","unstructured":"MC E. Gemstracker, (GEneric Medical Survey Tracker): Erasmus MC, Rotterdam; 2022. Available from: https:\/\/gemstracker.org\/."},{"issue":"2","key":"2715_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10545-015-9889-6","volume":"39","author":"D G\u00fcng\u00f6r","year":"2016","unstructured":"G\u00fcng\u00f6r D, Kruijshaar ME, Plug I, Rizopoulos D, Kanters TA, Wens SC, et al. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. J Inherit Metab Dis. 2016;39(2):253\u201360.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2715_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ymgme.2013.03.016","volume":"109","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, de Vries JM, Brusse E, Kruijshaar ME, Hop WC, Murawska M, et al. Enzyme replacement therapy and fatigue in adults with Pompe disease. Mol Genet Metab. 2013;109(2):174\u20138.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"2715_CR29","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00415-006-0434-2","volume":"254","author":"ML Hagemans","year":"2007","unstructured":"Hagemans ML, van Schie SP, Janssens AC, van Doorn PA, Reuser AJ, van der Ploeg AT. Fatigue: an important feature of late-onset Pompe disease. J Neurol. 2007;254(7):941\u20135.","journal-title":"J Neurol"},{"issue":"Pt 3","key":"2715_CR30","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/brain\/awh384","volume":"128","author":"ML Hagemans","year":"2005","unstructured":"Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, et al. Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients. Brain. 2005;128(Pt 3):671\u20137.","journal-title":"Brain"},{"issue":"3","key":"2715_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10545-014-9751-2","volume":"38","author":"JC van der Meijden","year":"2015","unstructured":"van der Meijden JC, G\u00fcng\u00f6r D, Kruijshaar ME, Muir AD, Broekgaarden HA, van der Ploeg AT. Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease. J Inherit Metab Dis. 2015;38(3):495\u2013503.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 2","key":"2715_CR32","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.21037\/jtd-cus-2020-007","volume":"12","author":"NM Shah","year":"2020","unstructured":"Shah NM, Sharma L, Ganeshamoorthy S, Kaltsakas G. Respiratory failure and sleep-disordered breathing in late-onset Pompe disease: a narrative review. J Thorac Dis. 2020;12(Suppl 2):S235\u201347.","journal-title":"J Thorac Dis"},{"issue":"2","key":"2715_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/ene.12582","volume":"22","author":"M Boentert","year":"2015","unstructured":"Boentert M, Karabul N, Wenninger S, Stubbe-Dr\u00e4ger B, Mengel E, Schoser B, et al. Sleep-related symptoms and sleep-disordered breathing in adult Pompe disease. Eur J Neurol. 2015;22(2):369\u201376.","journal-title":"Eur J Neurol"},{"issue":"9413","key":"2715_CR34","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S0140-6736(04)15794-2","volume":"363","author":"A Chaudhuri","year":"2004","unstructured":"Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet. 2004;363(9413):978\u201388.","journal-title":"Lancet"},{"issue":"5","key":"2715_CR35","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.apmr.2014.11.020","volume":"96","author":"MM Favejee","year":"2015","unstructured":"Favejee MM, van den Berg LE, Kruijshaar ME, Wens SC, Praet SF, Pim Pijnappel WW, et al. Exercise training in adults with Pompe disease: the effects on pain, fatigue, and functioning. Arch Phys Med Rehabil. 2015;96(5):817\u201322.","journal-title":"Arch Phys Med Rehabil"},{"key":"2715_CR36","doi-asserted-by":"crossref","unstructured":"Angelini C. Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC Consortium. Eur J Transl Myol. 2021;31(2).","DOI":"10.4081\/ejtm.2021.9798"},{"key":"2715_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13023-015-0303-0","volume":"10","author":"LE van den Berg","year":"2015","unstructured":"van den Berg LE, Favejee MM, Wens SC, Kruijshaar ME, Praet SF, Reuser AJ, et al. Safety and efficacy of exercise training in adults with Pompe disease: evalution of endurance, muscle strength and core stability before and after a 12 week training program. Orphanet J Rare Dis. 2015;10:87.","journal-title":"Orphanet J Rare Dis"},{"key":"2715_CR38","doi-asserted-by":"crossref","unstructured":"Korlimarla A, Lim JA, McIntosh P, Zimmerman K, Sun BD, Kishnani PS. New insights into gastrointestinal involvement in late-onset pompe disease: lessons learned from bench and bedside. J Clin Med. 2021;10(15).","DOI":"10.3390\/jcm10153395"},{"key":"2715_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/8904_2014_334","volume":"17","author":"N Karabul","year":"2014","unstructured":"Karabul N, Skudlarek A, Berndt J, Kornblum C, Kley RA, Wenninger S, et al. Urge incontinence and gastrointestinal symptoms in adult patients with pompe disease: a cross-sectional survey. JIMD Rep. 2014;17:53\u201361.","journal-title":"JIMD Rep"},{"issue":"2\u20133","key":"2715_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ymgme.2010.06.003","volume":"101","author":"DL Bernstein","year":"2010","unstructured":"Bernstein DL, Bialer MG, Mehta L, Desnick RJ. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Mol Genet Metab. 2010;101(2\u20133):130\u20133.","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"2715_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jns.2015.04.012","volume":"353","author":"J Pardo","year":"2015","unstructured":"Pardo J, Garc\u00eda-Sobrino T, L\u00f3pez-Ferreiro A. Gastrointestinal symptoms in late-onset Pompe disease: early response to enzyme replacement therapy. J Neurol Sci. 2015;353(1\u20132):181\u20132.","journal-title":"J Neurol Sci"},{"issue":"4","key":"2715_CR42","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ymgme.2012.05.007","volume":"106","author":"LD Hobson-Webb","year":"2012","unstructured":"Hobson-Webb LD, Proia AD, Thurberg BL, Banugaria S, Prater SN, Kishnani PS. Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature. Mol Genet Metab. 2012;106(4):462\u20139.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2715_CR43","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/mus.880100311","volume":"10","author":"JD van der Walt","year":"1987","unstructured":"van der Walt JD, Swash M, Leake J, Cox EL. The pattern of involvement of adult-onset acid maltase deficiency at autopsy. Muscle Nerve. 1987;10(3):272\u201381.","journal-title":"Muscle Nerve"},{"issue":"12","key":"2715_CR44","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/hmg\/8.12.2145","volume":"8","author":"AG Bijvoet","year":"1999","unstructured":"Bijvoet AG, Van Hirtum H, Kroos MA, Van de Kamp EH, Schoneveld O, Visser P, et al. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet. 1999;8(12):2145\u201353.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2715_CR45","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/(SICI)1096-9896(199911)189:3<416::AID-PATH445>3.0.CO;2-6","volume":"189","author":"AG Bijvoet","year":"1999","unstructured":"Bijvoet AG, Van Hirtum H, Vermey M, Van Leenen D, Van Der Ploeg AT, Mooi WJ, et al. Pathological features of glycogen storage disease type II highlighted in the knockout mouse model. J Pathol. 1999;189(3):416\u201324.","journal-title":"J Pathol"},{"issue":"12","key":"2715_CR46","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/labinvest.3700484","volume":"86","author":"BL Thurberg","year":"2006","unstructured":"Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest. 2006;86(12):1208\u201320.","journal-title":"Lab Invest"},{"key":"2715_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/8904_2015_426","volume":"23","author":"LD Pena","year":"2015","unstructured":"Pena LD, Proia AD, Kishnani PS. Postmortem findings and clinical correlates in individuals with infantile-onset Pompe disease. JIMD Rep. 2015;23:45\u201354.","journal-title":"JIMD Rep"},{"issue":"3","key":"2715_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","volume":"120","author":"J Chan","year":"2017","unstructured":"Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, et al. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab. 2017;120(3):163\u201372.","journal-title":"Mol Genet Metab"},{"key":"2715_CR49","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1540\/jsmr.54.100","volume":"54","author":"AL McCall","year":"2018","unstructured":"McCall AL, Salemi J, Bhanap P, Strickland LM, Elmallah MK. The impact of Pompe disease on smooth muscle: a review. J Smooth Muscle Res. 2018;54:100\u201318.","journal-title":"J Smooth Muscle Res"},{"issue":"6","key":"2715_CR50","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/MOP.0b013e3282f161f2","volume":"19","author":"TA Burrow","year":"2007","unstructured":"Burrow TA, Hopkin RJ, Leslie ND, Tinkle BT, Grabowski GA. Enzyme reconstitution\/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr. 2007;19(6):628\u201335.","journal-title":"Curr Opin Pediatr"},{"issue":"5","key":"2715_CR51","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","volume":"35","author":"C Regnery","year":"2012","unstructured":"Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, Grunert B, et al. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis. 2012;35(5):837\u201345.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"2715_CR52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000446154","volume":"169","author":"M Capanoglu","year":"2016","unstructured":"Capanoglu M, Dibek Misirlioglu E, Azkur D, Vezir E, Guvenir H, Gunduz M, et al. IgE-mediated hypersensitivity and desensitisation with recombinant enzymes in Pompe disease and type I and type VI mucopolysaccharidosis. Int Arch Allergy Immunol. 2016;169(3):198\u2013202.","journal-title":"Int Arch Allergy Immunol"},{"issue":"1\u20132","key":"2715_CR53","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ymgme.2011.07.004","volume":"104","author":"AH El-Gharbawy","year":"2011","unstructured":"El-Gharbawy AH, Mackey J, DeArmey S, Westby G, Grinnell SG, Malovrh P, et al. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. Mol Genet Metab. 2011;104(1\u20132):118\u201322.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2715_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26\u201333.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2715_CR55","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","volume":"39","author":"CM van Gelder","year":"2016","unstructured":"van Gelder CM, Poelman E, Plug I, Hoogeveen-Westerveld M, van der Beek N, Reuser AJJ, et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis. 2016;39(3):383\u201390.","journal-title":"J Inherit Metab Dis"},{"key":"2715_CR56","doi-asserted-by":"crossref","unstructured":"Poelman E, van den Dorpel J, Hoogeveen-Westerveld M, van den Hout J, van der Giessen LJ, van der Beek N, et al. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients. J Inherit Metab Dis. 2020.","DOI":"10.1002\/jimd.12268"},{"issue":"1","key":"2715_CR57","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12889-017-4189-8","volume":"17","author":"KL Cheung","year":"2017","unstructured":"Cheung KL, Ten Klooster PM, Smit C, de Vries H, Pieterse ME. The impact of non-response bias due to sampling in public health studies: A comparison of voluntary versus mandatory recruitment in a Dutch national survey on adolescent health. BMC Public Health. 2017;17(1):276.","journal-title":"BMC Public Health"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02715-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02715-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02715-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T13:09:52Z","timestamp":1683551392000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02715-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2715"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02715-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"13 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the medical ethical committee of the Erasmus MC (MEC-2019-0146). The institutional review board assessed the study not to be subject to the Medical Research Involving Human Subjects Act (WMO). We received informed consent from all participants and\/or their caregivers in this study; all forms are on file at the Erasmus MC and are available in case of request. All individual patient data was de-identified.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We received informed consent from all participants and\/or their caregivers in this study; all forms are on file at the Erasmus MC and are available in case of request. All individual patient data was de-identified.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ID, EB, and HH declare no competing interest. NvdB received funding for research, clinical trials, and advisory fees from Sanofi working on enzyme replacement therapy or next\u00adgeneration therapies in the field of Pompe disease, other lysosomal storage diseases or neuromuscular disorders, under an agreement between this company and Erasmus MC University Medical Center and the relevant industry. She also received a Veni grant from ZonMW: project no. 09150161910230. AvdP received funding for research, clinical trials, and advisory fees from Sanofi, Amicus Therapeutics, Spark Therapeutics, Denali Therapeutics and Takeda working on enzyme replacement therapy or next\u00adgeneration therapies in the field of Pompe disease, other lysosomal storage diseases or neuromuscular disorders, under agreements with Erasmus MC University Medical Center and the relevant industry. JvdH received funding for research, clinical trials, and advisory fees from Sanofi, Denali therapeutics, Amicus Therapeutics and Takeda working on enzyme replacement therapy or next\u00adgeneration therapies in the field of Pompe disease, other lysosomal storage diseases or neuromuscular disorders, under agreements with Erasmus MC University Medical Center and the relevant industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}